ovarian cancer - Sports Zone
AOL: Drug for rare disease could be used to extend lives of ovarian cancer patients, study finds A drug typically used for a rare disorder could extend the lives of patients battling a form of ovarian cancer, a study has found. Women diagnosed with platinum-resistant ovarian cancer, a type where ... Drug for rare disease could be used to extend lives of ovarian cancer patients, study finds MedPage Today: Radon and Ovarian Cancer; Melanoma Drug Rejected; Missed Chances for Genomic Testing High levels of residential radon were linked to a roughly 30% higher risk for ovarian cancer in postmenopausal women, an analysis of the Women's Health Initiative showed.
Understanding the Context
( JAMA Network Open) ... Radon and Ovarian Cancer; Melanoma Drug Rejected; Missed Chances for Genomic Testing SciTechDaily: Researchers Discover Surprising New Ovarian Cancer Treatment Using an Existing Drug Researchers have uncovered an early survival response in ovarian cancer cells that may limit the effectiveness of widely used PARP inhibitors. Sky News: Pill for Cushing's syndrome could benefit patients with treatment resistant ovarian cancer, study suggests On average, patients with platinum-resistant ovarian cancer only live for around one year to 18 months after diagnosis. Pill for Cushing's syndrome could benefit patients with treatment resistant ovarian cancer, study suggests A newly identified interaction between ovarian cancer cells and surrounding abdominal cells helps explain the cancer’s unusually fast and aggressive spread.
Image Gallery
Key Insights
MarketWatch: Zentalis Pharmaceuticals Climbs on Selection of Higher Dose for Ovarian-Cancer Trials Shares of Zentalis Pharmaceuticals rose after the company selected a higher dose of azenosertib to treat ovarian cancer in two clinical trials. The stock gained 49%, to $4.12, Thursday afternoon after ... SurvivorNet on MSN: Newly approved ovarian cancer treatment combination with the drug Lifyorli helps give time after relapse The FDA has approved Lifyorli (relacorilant) plus Abraxane for certain platinum‑resistant ovarian cancer patients, offering a new option after prior treatments stop working. Newly approved ovarian cancer treatment combination with the drug Lifyorli helps give time after relapse Cancer Therapy Advisor: Mortality Risk Steadily Declines for Long-Term Ovarian Cancer Survivors Investigators compared mortality risk among long-term survivors of high-grade serous ovarian cancer versus the general US population to examine how mortality and recurrence trends have changed with ... These data were simultaneously published in The Lancet: “ Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised ...
Related Articles You Might Like:
what's the score of thursday night football is heat or ice better for muscle spasms how to get get rid of belly fat fastFinal Thoughts
Continuing a tradition in an effort to raise awareness and find a cure for ovarian cancer, the National Ovarian Cancer Coalition is hosting their annual Teal Lights cruise next month. Tickets are ...